secwatch.observer — SEC 8-K summary
======================================

Issuer:     MetaVia Inc. (MTVA)
CIK:        0001638287
Form:       8-K
Filed at:   2025-04-15T23:59:59+00:00
Accession:  0001558370-25-004796
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MetaVia reports positive Phase 1 MAD data for DA-1726 obesity drug: 6.3% max weight loss, strong glucose control
--------------------------------------------------------------------------------

- Mean weight loss 4.3% (max 6.3%) at 32 mg dose on Day 26 (p=0.0005).
- Fasted glucose lowered by mean 5.3 mg/dL (max 18 mg/dL); waist circumference reduced mean 1.6 in (max 3.9 in).
- No SAEs or discontinuations; mild GI AEs transient, 83% of 32 mg cohort reported early satiety.
- Adding higher-dose cohorts to determine MTD; planning Phase 1 Part 3 in Wegovy early drop-out patients.
- Company cites balanced GLP-1/glucagon activation as potential best-in-class profile for safety and efficacy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638287/000155837025004796/0001558370-25-004796-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638287/000155837025004796/mtva-20250415x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-004796

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer